BIOMAT Database Logo BIOMAT Database Logo

Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. 1989

A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
1st Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

To investigate the differential stages of B cell activation in patients with systemic lupus erythematosus (SLE), the effects of recombinant interleukin-4 (rIL-4) interleukin-6 (rIL-6), and low mol. wt BCGF (1-BCGF) on B cell proliferation and differentiation were evaluated. In a co-stimulatory assay with anti-IgM, proliferative response to rIL-4 and 1-BCGF showed no significant differences between SLE patients and healthy controls. In a restimulation assay, after pre-activation with anti-IgM for 3 days, proliferative response to rIL-4 and 1-BCGF was significantly decreased in SLE patients compared with normal healthy controls (P less than 0.01). With regard to rIL-6 induced B cell differentiation, SAC-pre-activated low density, large B cells from both SLE patients and healthy controls differentiated well, whereas high density B cells did not differentiate at all. Of particular interest, low density B cells from active patients directly differentiated into Ig secreting cells in response to rIL-6 without SAC activation. These data indicate that heterogeneity of B cell responsiveness to B cell-tropic interleukins resulted from the discrete stages of B cell activation in SLE.

UI MeSH Term Description Entries
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2

Related Publications

A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
B cell hyperactivity in systemic lupus erythematosus: selectively enhanced responsiveness to a high molecular weight B cell growth factor.
October 1986, European journal of immunology,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Characterization of B cell growth in systemic lupus erythematosus. Effects of recombinant 12-kDa B cell growth factor, interleukin 4 and transforming growth factor-beta.
November 1990, European journal of immunology,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Hyperreactivity of activated B cells to B cell growth factor in patients with systemic lupus erythematosus.
December 1989, Journal of immunology (Baltimore, Md. : 1950),
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Abnormal production of B cell growth factor in patients with systemic lupus erythematosus.
July 1992, Clinical and experimental immunology,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Factor B activation in systemic lupus erythematosus.
October 1990, Arthritis and rheumatism,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Low molecular weight C1q in systemic lupus erythematosus.
July 1985, Journal of immunology (Baltimore, Md. : 1950),
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
[Interleukin 2 receptor positive B cells and its responsiveness to human recombinant interleukin 2 in patients with systemic lupus erythematosus].
June 1987, Rinsho byori. The Japanese journal of clinical pathology,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Interleukin 2 receptors and responsiveness to recombinant human interleukin 2 in patients with systemic lupus erythematosus.
January 1987, Mayo Clinic proceedings,
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus.
May 1999, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
A Kitani, and M Hara, and T Hirose, and K Norioka, and M Harigai, and W Hirose, and K Suzuki, and M Kawakami, and M Kawagoe, and H Nakamura
Clinical significance of low molecular weight IgM in patients with systemic lupus erythematosus.
October 1984, The Journal of rheumatology,
Copied contents to your clipboard!